Overview

Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy

Status:
Recruiting

Trial end date:
2024-03-30

Target enrollment:

Participant gender:

Summary

To assess the efficacy (in terms of response rate and duration) of the infusion of ARI-0001 cells (Adult differentiated autologous T-cells from peripheral blood, expanded and transducted with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity [A3B1] conjugated to the 4-aBB and CD3z co-stimulatory regions) in patients with resistant or refractory CD19+ acute lymphoid leukemia

Phase:

Phase 2

Details

Lead Sponsor:

Sara V. Latorre

Collaborators:

Institut d'Investigacions Biomèdiques August Pi i Sunyer
Instituto de Salud Carlos III